tiprankstipranks
Trending News
More News >

Jasper Therapeutics presents data from SPOTLIGHT Phase 1b/2a study

Jasper Therapeutics (JSPR) is presenting data from the 180mg cohort of the Company’s SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress. Briquilimab administration resulted in deep disease control at 180mg, with 12 of 12 participants enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants achieving clinical response by week 2, and 7 of 12 participants maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1